

## Propiverina

### Descrizione del farmaco

Antispastici urinari – G04BD06

**Mictonorm®** SIGMATAU INDUSTRIE FARMACEUTICHE RIUNITE  
28 cpr riv **15 mg** - € 30,00

Classe C – Tipo di ricetta: **RR**

Procedura di registrazione: **mutuo riconoscimento**

### Indicazione del nuovo principio attivo

Trattamento sintomatico dell'incontinenza urinaria e/o dell'aumentata frequenza e urgenza urinaria, che può presentarsi nei pazienti con sindrome della vescica iperattiva o con iperattività detrusoriale neurogena (iperflessia detrusoriale) dovuta a lesioni del midollo spinale, ad es. paraplegia da sezione trasversa.

### Il nostro giudizio

**Per i pazienti con vescica iperattiva o iperattività detrusoriale neurogena, propiverina non apporta alcun vantaggio in termini di efficacia o di sicurezza né rispetto ad oxibutinina, unico farmaco a carico del SSN e molto più economico, né rispetto a tolterodina. Il suo utilizzo non è pertanto raccomandato.**

### Bibliografia

1. Corongiu M et al. Prescrizione off-label. Dialogo sui Farmaci 2011; 4: 170-1.
2. Pagliarulo A et al. Linee guida 2008. Società Italiana di Urologia [www.siu.it/contents/view/165](http://www.siu.it/contents/view/165) (accesso del 05.08.2011).
3. Carone A. Linee guida sull'incontinenza. Raccomandazioni ICI 2009. Traduzione italiana. Fondazione Italiana Incontinenza. [www.contenuti-web.com/saratimages/areasanitaria\\_dwnld1\\_118.pdf](http://www.contenuti-web.com/saratimages/areasanitaria_dwnld1_118.pdf) (accesso del 7.09.2011).
4. NICE 2006. Urinary incontinence. <http://guidance.nice.org.uk/CG40> (accesso del 7.09.2011).
5. Propiverine. R&D Insight. 2010 Adis Data Information.
6. Mictonorm®. Riassunto delle caratteristiche del prodotto.
7. Stöhrer M et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, double-blind, multicenter clinical study. Eur Urology 2007; 51: 235-42.
8. Madersbacher H et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International 1999; 84: 646-51.
9. Abrams P et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13: 692-8.
10. Jünemann KP et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. EurUrol 2005; 48: 478-82.
11. Dorschner W et al. Efficacy and cardiac safety of propiverine in elderly patients. A double blind, placebo controlled clinical study. Eur Urol 2000; 37: 702-8.

12. Lee KS et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU Int 2009; 105: 1656-70.

13. Stöhrer M et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia. A double blind, placebo controlled clinical trial. Spinal Cord 1999; 37: 196-200.

14. Alloussi S et al. Treatment of the urge syndrome with propiverine in the therapeutic practice. Urologe 2000; 40: 367-73.

15. Choo MS et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2000; 174: 201-4.

16. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006; 68: 17-28.

17. Brubakerl et al. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006; 68: 3-8.

18. EMA 2002. Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence. [www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2009/09/WC500003350.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003350.pdf) (accesso del 5.09.2011).